PHAR · Pharming Group N.V.
$11.72
-0.63 (-5.10%)
At close · Aug 14
Market Cap
$8.22B
Shares
701.68M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.72
Open$11.92
Day$11.67–12.51
52W close$9.82–21.18
Avg vol 30d16K
Short int19K · 0.0% float · 2.0d
Short vol77%
Last earningsJul 30, 2026
DataDec 2020–Aug 2026
Up next
Next earnings call
Oct 30, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−24%
below
Price vs 50-day avg
−7%
below
RSI (14)
47
neutral
MACD trend
Positive
52-week position
17%
mid-range
Momentum
relative strength
1-month return
−13%
trailing
6-month return
−30%
trailing
YTD return
−34%
this year
Relative strength
−44%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $15 — 200d above 50d
Institutional flow
Accumulating
+42% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · ▲ +93.0% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
17 holders — near 3-yr high, broad support
Squeeze score
49
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
68%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Revenue
· 2026
$405M – $425M
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Total revenues
· full-year 2025
$360M – $375M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−24%
Bearish
Price vs 50-day avg
−7%
Bearish
RSI (14)
47
Neutral
MACD trend
Positive
Bullish
52-week position
17%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $13 › 200d $15 — 200d above 50d
Institutional flow
Accumulating
+42% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · ▲ +93.0% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
17 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $10
Now $12 · 17%
Range high $21
vs 200-day avg -24%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PHAR
this stock
Pharming Group N.V.
|
$8.22B | -33.7% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PHAR | +7.0% | -13.0% | -30.1% | +16.3% | -33.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +6.6% | -17.4% | -43.8% | +12.4% | -47.5% |
Key facts
CIK
1828316
CUSIP
71716E105
13F (30d)
15 filings
15 filers
Visit website
Investor relations